Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, Azelnidipine, in hypertensive patients

Internal Medicine

Volumn 49, Issue 7, 2010, Pages 637-643

  Kondo, Tatsuya ^a,b   Goto, Rieko ^a   Sonoda, Kazuhiro ^b   Yasuda, Takeomi ^a,b   Ono, Kaoru ^a   Takaki, Yuki ^a   Yatsuda, Riichiro ^b   Miyamura, Nobuhiro ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Yatsuda Hospital   (Japan)

Author keywords

Aldosterone renin ratio (ARR); Azelnidipine; Plasma aldosterone concentration (PAC); Plasma renin activity (PRA)

Indexed keywords

ALDOSTERONE; AMLODIPINE; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; MANIDIPINE; NIFEDIPINE; RENIN; AZETIDINE 2 CARBOXYLIC ACID; DIHYDROPYRIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MALE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; SCREENING TEST; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALDOSTERONE; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENIN;

EID: 77950575060     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2749     Document Type: Article

References (17)

1. Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J 54: 487-495, 2007.
2. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism-part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 21: 447-454, 2008.
3. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66: 607-618, 2007.
4. Mulatero P, Caserta M, Bertello C, et al. Aldosterone as an independent factor in cerebrovascular damage. Clin Exp Hypertens 30: 785-797, 2008.
5. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40: 897-902, 2002.
6. Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 33: 186-192, 1999.
7. Nakamura T, Saito Y, Saito T, Kurabayashi M. Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats. J Pharmacol Sci 102: 239-242, 2006.
8. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 29 (Suppl): S1-S105, 2006.
9. Wenzel RR, Bruck H, Noll G, Schafers RF, Daul AE, Philipp T. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 35 (7 Suppl 4): S43-S52, 2000.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation Sep 1; 92: 1326-1331, 1995.
11. Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 57: 698-704, 2007.
12. Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 52: 555-560, 2008.
13. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 28: 1017-1023, 2005.
14. Chung S, Park CW, Shin SJ, et al. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant Sep 11: 2009 [Epub ahead of print].
15. Fujimoto SMS, Komai N, Kashihara N. Effects of azelnidipine on renal microcirculation. Prog Med 24: 2670-2675, 2004.
16. Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol Mar 605: 49-52, 2009.
17. Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51: 742-748, 2008.